Dr. Leonard Klein
Claim this profileIllinois Cancer Specialists
Studies Lymphoma
Studies B-Cell Lymphoma
10 reported clinical trials
26 drugs studied
Area of expertise
1Lymphoma
EZH2 positive
CNG positive
CNG negative
2B-Cell Lymphoma
Affiliated Hospitals
Clinical Trials Leonard Klein is currently running
Lenalidomide + Dexamethasone +/- Daratumumab
for Multiple Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria
JCAR017
for Non-Hodgkin's Lymphoma
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This study is divided into three periods: * Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation; * Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with follow-up through Day 29; * Posttreatment, which includes follow-up assessments for disease status and safety for 5 years.
Recruiting1 award Phase 27 criteria
More about Leonard Klein
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Leonard Klein has experience with
- Rituximab
- Lenalidomide
- Cyclophosphamide
- Brentuximab Vedotin
- Abemaciclib
- Tazemetostat
Breakdown of trials Leonard Klein has run
Lymphoma
B-Cell Lymphoma
Leukemia
Breast Cancer
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Leonard Klein specialize in?
Leonard Klein focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved EZH2 positive patients, or patients who are CNG positive.
Is Leonard Klein currently recruiting for clinical trials?
Yes, Leonard Klein is currently recruiting for 3 clinical trials in Arlington Heights Illinois. If you're interested in participating, you should apply.
Are there any treatments that Leonard Klein has studied deeply?
Yes, Leonard Klein has studied treatments such as Rituximab, Lenalidomide, Cyclophosphamide.
What is the best way to schedule an appointment with Leonard Klein?
Apply for one of the trials that Leonard Klein is conducting.
What is the office address of Leonard Klein?
The office of Leonard Klein is located at: Illinois Cancer Specialists, Arlington Heights, Illinois 60005 United States. This is the address for their practice at the Illinois Cancer Specialists.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.